US Patent

US12447141 — Liquid tasimelteon formulations and methods of use thereof

Method of Use · Assigned to Vanda Pharmaceuticals Inc · Expires 2040-12-11 · 15y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects liquid formulations of tasimelteon and methods for their use.

USPTO Abstract

Liquid suspensions of tasimelteon and methods for their use.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-3003`	—

Patent Metadata

Patent number: US12447141
Jurisdiction: US
Classification: Method of Use
Expires: 2040-12-11
Drug substance claim: No
Drug product claim: No
Assignee: Vanda Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.